US Stock MarketDetailed Quotes

APLT Applied Therapeutics

Watchlist

5.090
-0.050-0.97%

Close Jul 22 16:00 ET

5.090
0.0000.00%

Post 16:10 ET

581.62MMarket Cap-2664P/E (TTM)

Applied Therapeutics Stock Forum

Jensen 108

Jul 15 12:31

$Applied Therapeutics(APLT.US)$ tiny stocks with consistent performance. Just brought 3 weeks.

Applied Therapeutics(APLT) 5.750 +3.60%

Jensen 108

Jul 15 11:41

Share Your Profit/Loss

Jensen 108

Jun 27 12:57

$Applied Therapeutics(APLT.US)$ keep up the early momentum

Stoic Trader

Jun 21 14:39

$Applied Therapeutics(APLT.US)$ Dip buying on consolidating aiming for highs of 7ish or 8
$Applied Therapeutics(APLT.US)$

SpyderCall

May 15 15:51

Will we catch support at that 30-week moving average again?

$Applied Therapeutics(APLT.US)$

Trytosaveabit

Apr 4 06:33

See what comes from this? Along with my post from 3/28! LIKE!

$Applied Therapeutics(APLT.US)$ Applied Therapeutics Plans To Present Results From Phase 3 ARISE-HF Study In Diabetic Cardiomyopathy At ACC 2024

Trytosaveabit

Mar 28 16:06

Make a note!

$Applied Therapeutics(APLT.US)$ Applied Therapeutics said regulators had extended the period for reviewing its application for a rare metabolic disease treatment.
The biopharmaceutical company said Thursday that the Food and Drug Administration now has a target action date of Nov. 28 for its application, compared with the previous date of Aug. 28.
The company's application is for govorestat in the treatment of Galactosemia, a rare genetic condition that makes patients unable to metab...

Stock Region

Feb 28 17:55

Therapeutics Company Announce FDA Acceptance For New Galactosemia Treatment

Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia: A Revolution in Healthcare.
In a significant development for the healthcare sector and investors worldwide, Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company, has announced the Food and Drug Administration's acceptance and priority review of t...